CP and Behcet disease: For instance, eculizumab did not prevent the development of DGF,37 whereas patients who received C1INH needed fewer dialysis sessions 2–4 wk after transplantation and showed a better renal function 1 y after transplantation.38 A recent nonhuman primate study showed the possible beneficial effects of blocking complement activation in the donor.39 BD was induced in nonhuman primates who received recombinant human C1INH, which blocks the CP and LP, at 3-h intervals during 20 h of BD.